Severe bypophospbataemia in a patient with acute leukaemia I S Young, K Bailie l and E R Trimble
Large scale surveys have demonstrated that mild hypophosphataemia ( < O·70 mmol/L) is a relatively common finding among hospital inpatients, with an incidence of 2-3070. 1,2 Most patients are asymptomatic and do not require phosphate replacement therapy. Severe hypophosphataemia «0· 30 mmol/L), in contrast, is an uncommon finding,2,3 and frequently results in significant adverse effects. Severe hypophosphataemia is often multifactorial in origin and parenteral phosphate replacement may be required.
Factors which may contribute to hypophosphataemia include reduced phosphate intake, increased phosphate loss and a shift of phosphate into cells." Reduced phosphate intake may occur during starvation and phosphate reabsorption may be prevented by certain antacids. Increased urinary phosphate loss occurs in vitamin D resistant rickets, oncogenic hypophosphataemia and other renal tubular disorders. An intracellular phosphate shift is a common finding following refeeding of malnourished subjects, and also occurs during respiratory alkalosis, dextrose infusion and treatment of diabetic ketoacidosis. We report an unusual case in which recurrent severe symptomatic hypophosphataemia was caused by a shift of phosphate into a rapidly growing clone of tumour cells.
CASE REPORT
A 42-year-old woman with a 2 year history of intensively treated acute myelomonocytic leukaemia evolving from myelodysplasia of 4 years duration was admitted to the haematology unit of the Royal Victoria Hospital, Belfast, for investigation and treatment. Her recent course had been characterized by significant fluctuation in the peripheral white cell count (> 90% blasts) Correspondence: Dr I S Young.
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in association with variable splenomegaly. During periods of increasing white cell count she became weak and tired and had left sided upper abdominal pain due to splenic enlargement. The white cell count was readily controlled by modest doses of chemotherapy but bone marrow function was never significantly improved, necessitating red cell and platelet support. During the terminal phase of her illness the fluctuations were increasingly dramatic. Haemoglobin was maintained around 10 g/dL and platelets around 20 000 x 10 9 / L.
During one of the episodes of rapidly increasing white cell count, a progressive fall in serum phosphate to 0'12 mmol/L was noted. At this time, the patient complained of a smothering sensation in the chest and difficulty in breathing in the absence of a respiratory tract infection or any evidence of pulmonary oedema. There was no significant change in other biochemicalparameters. Arterial blood gases were not performed at this time in view of the low platelet count.
The degree of hypophosphataemia was confirmed by repeat measurement on freshly separated plasma and serum. In order to determine the cause of the patient's hypophosphataemia simultaneous fasting samples of urine and serum were obtained for measurement of phosphate and creatinine. The fractional excretion of phosphate (urinary phosphate/serum phosphate x serum creatinine/urine creatinine) was found to be less than o· 01. The predicted threshold for renal tubular phosphate reabsorption (maximum tubular reabsorption of phosphate [TmP] divided by glomerular filtration rate [GFR]) was calculated using the Bijvoet nomogram! and was found to be approximately 1· 20 mmol/L (reference range 0'7-1'4). This indicated that renal tubular phosphate conservation was normal. Two further measurements of TmP/GFR during the patient's hospital admission confirmed these findings.
The relationship between serum phosphate and peripheral white cell count is shown in Fig. 1 Hypophosphataemia due to the metabolic requirements of rapidly growing tumour cells has been infrequently reported in the past. Colman et al. reported a patient with a T cell lymphoma in whom serum phosphate fell to <0'05 mmollL during a period of rapid tumour expansion.s This was associated with severe generalised muscle weakness. Successful chemotherapy resulted in a rapid return to normal of serum phosphate levels and the resolution of symptoms. Hypophosphataemia, however, continued to recur periodically. Two similar cases have been reported in patients with acute Ieukaemias.P One of these subjects also had an acute myelomonocytic leukaemia (M4),7 and it is possible that cells of this type have a particularly high phosphate requirement during periods of rapid growth. It has also been shown that therapeutic infusions of certain cytokines and growth factors may cause hypophosphataemia by a similar mechanism."
More recently Coyle et al. 10 reported three cases of severe hypophosphataemia, including one in a patient with acute leukaemia in which utilization of phosphate by rapidly growing tumour cells apparently contributed to the hypophosphataemia. However, in this case urinary phosphate loss due to renal tubular damage following chemotherapy was also a factor. They suggested that in the presence of severe hypophosphataemia depletion of intracellular phosphate would occur in renal tubular cells, potentially interfering with reabsorption of urinary phosphate and reducing the usefulness of TmP/GFR. We have found no evidence of this phenomenon in our case. It is possible that more long standing depletion of phosphate is required before renal tubular cell ATP levels are reduced to an extent sufficient to impair phosphate reabsorption from urine. Severe hypophosphataemia may adversely affect most of the major organ systems." In particular, severe muscular weakness may occur. The diaphragm may be affected, and patients in intensive care with hypophosphataemia are more difficult to wean from a ventilator. The smothering sensation which occurred in our patient at the time of the lowest serum phosphate levels may have been partly due to this, although other factors such as intrapulmonary sequestration and arteriovenous shunting may have contributed. Cardiac muscle may also be affected, and left ventricular failure and cardiomyopathy may develop. Reduction in the erythrocyte content of 2,3-diphosphoglycerate can occur, with a resulting shift to the left of the oxygen dissociation curve. This may impair release of oxygen and can be associated with significant tissue hypoxia. Neutrophil and platelet dysfunction also occur. In this respect, the patient was noted clinically to Phosphat. I1Ijllocement 1heropy I phosphate measurements on blood incubated at 37°C in vitro prior to separation of plasma showed no change, excluding the possibility that hypophosphataemia was due to in vitro utilization of phosphate before measurement. As no other cause of hypophosphataemia was present, we concluded that phosphate was being extracted from the extracellular fluid to meet the requirements of the rapidly dividing clone of tumour cells. Intravenous phosphate supplementation was commenced at a rate of 20 mmoll24 h. Around the same time the patient was commenced on chemotherapy using etoposide and cytosine arabinoside. There was a progressive rise in her serum phosphate (which was monitored daily), along with a fall in the white cell count and an improvement in her general wellbeing. Phosphate supplementation was halted when her serum phosphate neared normal levels. No significant complications of phosphate replacement were observed, although there was a slight fall in serum calcium to 1.88 mmol/L. The white cell count fell to a minimum of Q'8x 10 9/L, at which stage serum phosphate was normal at 1·04 mmollL. Unfortunately, however, the tumour response was very short lived and there was a further rapid increase in the white cell count beginning 17 days after the final hospital admission. This was again associated with a fall in serum phosphate despite the resumption of phosphate supplementation. It was decided that further active treatment of the leukaemia would not be effective and the patient was given supportive care and eventually died. 
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Ul Young, Bailie and Trimble appear more haemorrhagic around the time when serum phosphate reached its nadir, despite no significant change in the platelet count at that time (24 ()()() x 10 9/L). Neurological symptoms range from mild disturbances of higher cerebral function to convulsions and coma-our patient was intermittently confused while her phosphate was low, although this may have been in part attributable to leucostasis due to the high white cell count.
CONCLUSION
This was an unusual case in which severe symptomatic hypophosphataemia developed as a result of the high phosphate demands of an activelydividingclone of tumour cells. Laboratories serving haematology units should be aware of the phenomenon.
